Director of the SNP&SEQ Technology Platform
and Research group leader:

 Prof. Ann-Christine Syvänen
Email: Ann-Christine.Syvanen@medsci.uu.se
Phone: 46 (0) 18 471 46 8846 (0) 18 471 46 88
Mobile: 46 (0) 70 167 94 4546 (0) 70 167 94 45

 

SNP-Genotyping inquiries:
 Tomas Axelsson, Manager - SNP-genotyping
Email: Tomas.Axelsson@medsci.uu.se
Phone: 46 (0) 18 471 46 9346 (0) 18 471 46 93
Mobile: 46 (0) 70 167 94 5846 (0) 70 167 94 58

 

Sequencing inquiries:
 Ulrika Liljedahl, Manager - Illiumina sequencing
Email: seq@medsci.uu.se
Phone: 46 (0) 18 471 46 9946 (0) 18 471 46 99
Mobile: 46 (0) 70 167 94 5946 (0) 70 167 94 59


Mail address:
                SNP&SEQ Technology Platform
                Biomedical Centre, BMC
                Box 1432
                SE-751 44 Uppsala
                Sweden

Shipping address:
                SNP&SEQ Technology Platform
                Biomedical Centre, BMC
                Husargatan 3, Box 1432
                SE-752 37 Uppsala


 

The research group of Molecular Medicin and the SNP&SEQ Technology Platform are located in BMC, corridors B11:1, C10:1 and D11:2.


 

Find BMC on

News

New R&D manager at the SEQ-platform

2014-03-01

Jessica Nordlund has joined the SNP&SEQ Technology Platform as manager for research and development.

Science for Life Laboratory joins the Illumina Genome Network

2014-02-24

Illumina announced today that Science for Life Laboratory in Sweden has joined the Illumina Genome Network to provide researchers with broader access to Illumina’s whole genome sequencing technology. Read the press release here!

VR-RFI grants funding to the SNP&SEQ Platform

2013-11-13

The Council for Research Infrastructures (VR-RFI) has granted 4.5 million SEK as support for 2014 to the SNP&SEQ Technology Platform in Uppsala. The decision corroborates the role of the SNP&SEQ Platform as a national infrastructure for Genomics. Recently, the SNP&SEQ Platform was assigned as a national infrastructure by SciLifeLab Sweden.

More HiSeq machines

2013-10-06

The Board of the National SciLifeLab has granted funding for a new HiSeq 2500 instrument to boost the sequencing capacity of the SNP&SEQ Platform. Uppsala University Hospital has granted additional funds towards a second new HiSeq 2500 instrument to be dedicated to clinical diagnostics for genetic diseases and cancer.

Large epigenetic study of acute leukemia

2013-09-24

The Molecular Medicine group, together with pediatric oncologists from several Swedish University Hospitals and hospitals in the Nordic countries, present a large epigenetic study of pediatric acute lymphoblastic leukemia, published in Genome Biology.

New publication in Nature

2013-09-15

In collaboration with several European research institutes, researchers from Molecular Medicine group and SNP&SEQ platform today present a map of genetic causes of differences between people. The study, published in Nature and Nature Biotechnology, describes the largest amount of data linking variations in the human genome with gene activity at the RNA level.

New equipment

2013-01-07

During Christmas the SNP&SEQ-platform installed a new HiSeq 2500-instrument. This instrument allows sequencing of 2 x 150 bp  and decreases the run time from 11 days to 27 hours. Currently the SNP&SEQ-platform offers sequencing using four HiSeq- and one MiSeq-instrument.

Publication i Nature Genetics

2012-12-02

15 new loci for coronary artery disease were published on-line in Nature Genetics on December 2nd. Both the molecular medicine group and the SNP&SEQ platform were involved in the study.